FindTrial
Sign In

GENETIC STUDY OF ALDOSE REDUCTASE GENE IN PATIENT WITH DIABETIC NEUROPATHY

STUDY OF ALDOSE REDUCTASE GENE POLYMORPHISM IN PATIENT WITH DIABETIC NEUROPATHY WITH REFERENCE TO ITS PREDICTIVE VALUE FOR THERAPEUTIC RESPONSE TO AR INHIBITOR

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2015/10/006319
Enrollment
100
Registered
2015-10-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients with diabetes less than 5 years having neuropathy

Interventions

Intervention1: Alrista SR: Alrista SR 150mg 1 OD

Sponsors

Department of Endocrinology
Lead Sponsor
Indian Council of Medical Research
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Male and female patients age between 30-65 years with diabetes duration not more than 5 years

Exclusion criteria

Exclusion criteria: Any known rheumatic disease, vitamin B12 deficiency, drug abuse hypothyroidism ,alcoholism, paraneoplastic disorder, leprosy, cerebral vascular disease, parkinsonism, Uremia, acute or chronic musculoskeletal disorders, chronic renal failure, chronic liver disease, chronic air ways disease, carcinoma infection, critical illness, patients on INH any known agent to neuropathy will be excluded.

Design outcomes

Primary

MeasureTime frame
improvement in glycemiaTimepoint: 90 DAYS—

Secondary

MeasureTime frame
improved nerve sensationTimepoint: 30DAYS & 90DAYS—

Countries

India

Contacts

Public ContactDr S K SINGH

Institute of Medical Sciences

balramgupta84@gmail.com9451196708

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026